Ionis Pharmaceuticals moves forward with FDA review of donidalorsen for HAE
In a significant development for hereditary angioedema (HAE) patients, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted ... Read More
Takeda’s TAKHZYRO approved by EC for pediatric hereditary angioedema
Takeda has announced a significant advancement in the treatment of Hereditary Angioedema (HAE), with the European Commission's approval of TAKHZYRO (lanadelumab) for routine prevention in ... Read More
Aurobindo Pharma’s subsidiary Eugia Pharma gets FDA approval for Icatibant Injection
In a pivotal move bolstering its footprint in the global pharmaceutical landscape, Aurobindo Pharma Limited's subsidiary, Eugia Pharma Specialities Limited, has achieved final authorization from ... Read More
Ionis Pharmaceuticals begins donidalorsen phase 3 trial in hereditary angioedema
Ionis Pharmaceuticals, a US-based developer of RNA-targeted therapies, has launched the OASIS-HAE phase 3 clinical trial for donidalorsen (formerly IONIS-PKK-LRx) in patients having hereditary angioedema ... Read More